Balansag, Rodelia B.
HRN: 08-69-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/05/2023
CO-AMOXICLAV 625MG (TAB)
11/07/2023
11/16/2023
PO
625mg
TID
Abscess, Supraorbital Area, Cutaneous
Checking Final Appropriateness
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes